Global Migraine Drugs Market Research Report: By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices), By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2027
Market Highlights
According to MRFR analysis, the global migraine drugs market is expected to register a CAGR of 5.9% during the forecast period of 2019 to 2025 and was valued at USD 4.4 billion in 2018.
Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels. Approximately 12% of the US population suffered from migraine headaches in 2018. The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain.
The growth of the global migraine drugs market is driven by various factors such as an increasing global geriatric population, rising prevalence of migraine, growing awareness about migraine in developing economies, rising R&D investment for the development of innovative drugs for the treatment of migraine, and increasing demand for better treatment methods for migraine. However, stringent government regulations, high investment required for drug research & development, and side-effects of medications prescribed for migraine are the factors that are expected to limit the growth of the global migraine drugs market during the forecast period.
Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8379
The global migraine drugs market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. Migraine treatment drugs available are approved for the acute form of the condition, led by generic triptans as the first-line treatment. The global migraine treatment market is witnessing a rapid shift in terms of strong R&D with the launch of CGRP-based therapies and approval of novel drug classes such as ditans, gepants, and reformulation of triptans for the treatment of both chronic and episodic migraine. Launch of late-stage pipeline products such as erenumab, galcanezumab, fremanezumab, and eptinezumab by major players such as Eli Lilly and Company, Alder Pharmaceuticals, Inc., Teva Pharmaceuticals Ltd, and Amgen strengthened its market position in the global migraine drugs market in 2018.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to be the largest market owing to the increasing prevalence of migraine and R&D by major players in the region. For instance, in September 2018, Eli Lilly and Company launched Emgality (galcanezumab-gnlm) injection (300 mg) for the preventive treatment of migraine in adults. It is the first drug to receive Food and Drug Administration (FDA) approval for decreasing the frequency of episodic cluster headache attacks. The migraine drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
The European migraine drugs market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The migraine drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Growing geriatric population, increasing patients suffering from neurological diseases, raising awareness about migraine, government initiatives in emerging economies to provide better healthcare infrastructure, and strategic initiatives by regional and market leaders are driving the migraine market in Asia-Pacific. The Asia-Pacific region is expected to be the fastest-growing during the forecast period.
The migraine drugs market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The global migraine drugs market has been segmented based on type, treatment, drug class, and end user.
The global migraine drugs market has been segmented, on the basis of migraine-type into episodic migraine and chronic migraine.
The global migraine drugs market has been segmented, on the basis of treatment type, into, acute, preventive, neuromodulation, and others.
The acute segment is expected to hold the majority share of the market as the prevalence of acute migraine is high, and most of the drugs manufactured by major companies are for the treatment of acute migraine.
The global migraine drugs market has been segmented, on the basis of drug class, into beta-blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others.
Triptons are the most preferred type of drugs class for migraine patients due to its high efficacy. It holds the major share in the market by drug class. Approximately 80% of the migraine patients are treated with Triptans, and more than 40% of the patients suffering from cardiovascular diseases with migraine were treated with triptans in 2018.
The market on the basis of end user has been segmented into hospitals and clinics, research and academic institutes, and others. The hospitals and clinics segment is expected to hold the largest share of the market as they are primary centers of treatment for the patient. The retail pharmacy segment offers over the counter (OTC) and prescription migraine drugs though a chain of pharmacies globally. Other end users include online pharmacy segment that offers OTC migraine drugs through e-commerce platforms.
Key Players
Some of the key players in the global migraine drugs market are Allergan Plc (Ireland), Alder Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), AstraZeneca Plc (UK), Johnson & Johnson Services, Inc. (US), Amgen Inc (US), Eli Lilly and Company, and eNeura Inc.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/migraine-drugs-market-8379
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds.The growth of the global migraine drugs market is driven by various factors such as an increasing global geriatric population, rising prevalence of migraine, growing awareness about migraine in developing economies, rising R investment for the development of innovative drugs for the treatment of migraine, and increasing demand for better treatment methods for migraine.
Some of the key players in the global migraine drugs market areAllergan Plc (Ireland)Alder Biopharmaceuticals Inc. (US)Pfizer Inc. (US)GlaxoSmithKline Plc (UK)Merck & Co. Inc. (US)Teva Pharmaceutical Industries Ltd (Israel)AstraZeneca Plc (UK)Johnson & Johnson Services Inc. (US)Amgen Inc (US)Eli Lilly and CompanyeNeura Incand OthersGet a Free Sample PDR @https://www.marketresearchfuture.com/sample_request/8379Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels.
Approximately 12% of the US population suffered from migraine headaches in 2018.
The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain.Market SegmentationThe global migraine drugs market has been segmented based on type, treatment, drug class, and end user.The global migraine drugs market has been segmented, on the basis of migraine-type into episodic migraine and chronic migraine.The global migraine drugs market has been segmented, on the basis of treatment type, into, acute, preventive, neuromodulation, and others.The acute segment is expected to hold the majority share of the market as the prevalence of acute migraine is high, and most of the drugs manufactured by major companies are for the treatment of acute migraine.The global migraine drugs market has been segmented, on the basis of drug class, into beta-blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others.
The Global Migraine Drugs Market size was valued at USD 1.80 billion in 2019 and is predicted to reach USD 2.44 billion by 2030, with a CAGR of 2.8% from 2020-2030.Migraine is a medical condition pertaining with primary headache disorder with symptoms such as nausea, vomiting, dry mouth, somnolence, and sensitivity to light or sound.
In some cases, patients are affected by prevalence of aura.
Migraine has no permanent cure, but migraine drugs can be used to reduce and prevent migraines.Access Full Description of this report at:-https://www.nextmsc.com/report/migraine-drugs-market Top Companies: Allergan Plc, Abbott Laboratories, AstraZeneca, Endo International Plc., Eisai Co. Ltd., Impax Laboratories, GlaxoSmithKline Plc., Johnson & Johnson, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Limited, Sanofi SA and others.According to the data provided by Migraine Trust in 2017, 1 in 7 people worldwide suffer from migraine, i.e.
2% of the total world population suffer from migraine; thereby, migraine being the third most common disease at global level.
However, side effects associated with the intake of migraine drugs are expected to restrict the growth of migraine drugs market.Request sample copy of this report at:-https://www.nextmsc.com/Migraine-Drugs-Market/request-sample The global migraine drugs market share has been analyzed based on type, route of administration, distribution channel and geography.
The preventive medicine is further divided into Anticonvulsant, Antidepressant, Beta Blocker, and others.
The global migraine drugs market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025.
On the contrary, the presence of growth opportunities in emerging nations is expected to provide new opportunities for the key players.Get Enquiry More About This Report:http://www.marketgrowthanalysis.com/reports/sample/210From the perspective of treatment, the global migraine drugs market is divided into- Abortive, and Prophylactic segments.
Further, Abortive segment is classified into triptans, alkoids, ergot and others based on the drug class.
Among these treatment segments, abortive procedure is likely to dominant market share in the global migraine drugs market whereas prophylactic treatment segment is projected to register a healthy growth during the forecast period that is from 2017 to 2025.On the basis of route of administration segment, the global migraine drugs market is mainly segmented into oral, injectable and others.
While on the basis of distribution channel the global migraine drugs market is segmented into hospital pharmacy and retail pharmacy.Some of the major players operating in the global migraine drugs market are Abbott, Aegis Theraputics, LLC, Aerial BioPharma LLC.
, Alder BioPharmaceuticals Inc., Amgen Inc., Astellas Pharma India Private Limited, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Johnson & Johnson Services, Inc, Eisai Co., Ltd., Eli Lilly and Company, Bayer AGSitemap., CoLucid, KOWA Pharmaceuticals America, Inc., Luitpold Pharmaceuticals, Inc., Klaria, Ethypharm, INTELGENX CORP., Global Information, Inc., LePro PharmaCompass OPC Private Limited, Zogenix, Inc., WINSTON PHARMACEUTICALS, Inc., Valeant, TG Therapeutics, Inc., Teva Pharmaceutical Industries Ltd, Horizon Pharma plc., Aralez Pharmaceuticals Inc., RedHill, Pfizer Inc, OptiNose US, Inc, Merck & Co. and Suda Ltd., among others.Get Request For Discount:http://www.marketgrowthanalysis.com/reports/enquiry/210The global migraine drugs market has been segmented as below:Global Migraine Drugs Market, by TreatmentAbortiveTriptansErgot AlkaloidsOthersProphylacticBotulinum ToxinTopiramateOthersGlobal Migraine Drugs Market, by Route of AdministrationOralInjectableOthers (Nasal Spray, Transdermal Patch, etc.
The Global Migraine Drug Market was valued at US$3.9 billion in the year 2018 and is expected to reach US$8.2 billion by 2026, at a CAGR of 9.73%.Migraine Drugs are a group of medication that is given for the relief of symptoms associated with migraine pain.
In the UK alone, the reported cases of migraine headaches each day extends to about 190,000, which is considered very high.
Also, the FDA has approved several drugs such as Aimovig for the prevention of chronic migraines, which may provide promising opportunities for the progress of the migraine drug market.
However, Botox is expected to face rivalry from launch of Amgen/Novartis' Aimovig which engrossed around US$ 59 million in 2019 Q1 sales and which is expected to reach more than US$ 1billion at the end of 2022and other exceptionally viable CGRP-based treatments, which targets both chronic and episodic migraine, unlike Botox, which is only approved for the chronic variant of the condition.Companies such as Pfizer Inc., GlaxoSmithKline plc, Allergan plc, Amgen Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Biohaven Pharmaceutical, Johnson and Johnson, and Bausch Health Companies Inc, etc., are also keen on launching their migraine drugs depending upon the competition, pricing of the competitors, etc.Optima Insights had classified the migraine drug market based on the route of administration, therapeutic class, treatment class, and regions.
The CGRP inhibitor propelled in Europe in July 2018 and North America during May 2018 and has received a positive reaction from patients and healthcare providers.Eli Lilly's Emgality (galcanezumab) also received FDA endorsement in October 2018.
Ajovy is the sole CGRP monoclonal therapeutic acting agent that gives patients quarterly and monthly dosing alternatives.The abortive drugs are utilized more in controlling the severity of migraine headaches and also to reduce the frequency of its occurrence.
